NASDAQ : MAZE
Maze Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 31.93 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.72B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Maze Therapeutics, Inc. (MAZE) reported revenue of 20.00M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | 20.00M | 167.50M | |||
| Gross Profit | 20.00M | 167.50M | |||
| Selling, General & Admin | 43.76M | 34.45M | 26.42M | 24.61M | 22.83M |
| Research & Development | 121.85M | 108.45M | 83.50M | 73.94M | 88.19M |
| Operating Expenses | 165.61M | 142.90M | 109.91M | 98.55M | 111.03M |
| Operating Income | -145.61M | -142.90M | 57.59M | -98.55M | -111.03M |
| Interest & Investment Income | 13.82M | 11.78M | 4.65M | 1.97M | 2.03M |
| Earnings From Equity Investments | -3.54M | ||||
| EBT Excluding Unusual Items | -133.59M | -131.12M | 62.24M | -96.58M | -112.54M |
| Gain (Loss) on Sale of Investments | -2.40M | ||||
| Other Unusual Items | -8.84M | -3.83M | |||
| Pretax Income | -133.59M | -131.12M | 53.40M | -100.42M | -114.94M |
| Income Tax Expense | 1.17M | ||||
| Net Income | -133.59M | -131.12M | 52.23M | -100.42M | -114.94M |
| Preferred Dividends & Other Adjustments | 48.83M | ||||
| Net Income to Common | -133.59M | -131.12M | 3.40M | -100.42M | -114.94M |
| Shares Outstanding (Basic) | 53.08M | 42.98M | 2.40M | 2.29M | 2.01M |
| Shares Outstanding (Diluted) | 53.08M | 42.98M | 2.73M | 2.29M | 2.01M |
| EPS (Basic) | -2.52 | -3.05 | 1.42 | -43.89 | -57.18 |
| EPS (Diluted) | -2.52 | -3.05 | 1.25 | -43.89 | -57.18 |
| Free Cash Flow | -106.84M | -112.73M | 74.81M | -87.27M | -101.17M |
| Free Cash Flow Per Share | -2.01 | -2.62 | 27.40 | -38.14 | -50.33 |
| Gross Margin | 100.00% | 100.00% | |||
| Operating Margin | -728.06% | 34.38% | |||
| Profit Margin | -667.95% | 2.03% | |||
| Free Cash Flow Margin | -534.20% | 44.66% | |||
| EBITDA | -143.71M | -140.50M | 60.88M | -94.46M | -107.21M |
| EBITDA Margin | 36.35% | ||||
| D&A For EBITDA | 1.91M | 2.40M | 3.30M | 4.09M | 3.82M |
| EBIT | -145.61M | -142.90M | 57.59M | -98.55M | -111.03M |
| EBIT Margin | 34.38% | ||||
| Effective Tax Rate | 2.20% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 202.64M | 189.25M | 196.81M | 29.16M | 99.92M |
| Short-Term Investments | 208.44M | 152.67M | |||
| Cash & Short-Term Investments | 411.09M | 341.92M | 196.81M | 29.16M | 99.92M |
| Other Receivables | 2.80M | 1.50M | |||
| Receivables | 2.80M | 1.50M | |||
| Prepaid Expenses | 6.54M | 6.30M | 4.86M | 4.95M | 6.23M |
| Total Current Assets | 420.42M | 349.72M | 201.67M | 34.11M | 106.15M |
| Property, Plant & Equipment | 22.83M | 25.16M | 29.92M | 34.98M | 41.23M |
| Long-Term Investments | 83.82M | 18.11M | |||
| Long-Term Deferred Charges | 4.60M | ||||
| Other Long-Term Assets | 4.55M | 4.14M | 4.35M | 2.41M | 2.58M |
| Total Assets | 531.62M | 397.13M | 240.54M | 71.50M | 149.96M |
| Accounts Payable | 2.21M | 1.79M | 1.94M | 2.02M | 1.58M |
| Accrued Expenses | 15.87M | 15.97M | 14.10M | 9.81M | 14.87M |
| Current Portion of Leases | 4.88M | 4.79M | 4.63M | 4.49M | 4.32M |
| Total Current Liabilities | 22.96M | 22.56M | 20.67M | 16.32M | 20.78M |
| Long-Term Debt | 38.96M | 20.08M | |||
| Long-Term Leases | 16.58M | 18.51M | 22.00M | 25.05M | 27.73M |
| Other Long-Term Liabilities | 1.09M | 969.00K | |||
| Total Liabilities | 78.50M | 42.16M | 43.64M | 61.45M | 48.51M |
| Common Stock | 56.00K | 49.00K | 2.00K | 2.00K | 21.00K |
| Additional Paid-In Capital | 1.01B | 844.35M | 47.24M | 21.84M | 12.79M |
| Retained Earnings | -558.48M | -489.55M | -358.43M | -395.69M | -295.27M |
| Comprehensive Income & Other | -435.00K | 110.00K | |||
| Total Common Equity | 453.12M | 354.97M | -311.18M | -373.85M | -282.46M |
| Shareholders' Equity | 453.12M | 354.97M | 196.90M | 10.05M | 101.44M |
| Total Liabilities & Equity | 531.62M | 397.13M | 240.54M | 71.50M | 149.96M |
| Total Debt | 60.42M | 23.31M | 26.63M | 49.62M | 32.05M |
| Net Cash (Debt) | 434.49M | 318.61M | 170.18M | -20.46M | 67.86M |
| Net Cash Per Share | 8.19 | 7.41 | 62.33 | -8.94 | 33.76 |
| Filing Date Shares Outstanding | 55.55M | 49.71M | 43.80M | 2.32M | 2.01M |
| Total Common Shares Outstanding | 55.50M | 49.33M | 2.44M | 2.32M | 2.01M |
| Working Capital | 397.46M | 327.16M | 181.00M | 17.79M | 85.37M |
| Book Value Per Share | 8.16 | 7.20 | -127.72 | -160.95 | -140.52 |
| Tangible Book Value | 453.12M | 354.97M | -311.18M | -373.85M | -282.46M |
| Tangible Book Value Per Share | 8.16 | 7.20 | -127.72 | -160.95 | -140.52 |
| Machinery | 17.96M | 17.31M | 16.47M | 16.08M | |
| Construction In Progress | 40.00K | 29.00K | 57.00K | ||
| Leasehold Improvements | 5.50M | 5.45M | 5.36M | 5.33M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -133.59M | -131.12M | 52.23M | -100.42M | -114.94M |
| Depreciation & Amortization | 1.91M | 2.40M | 3.30M | 4.09M | 3.82M |
| Loss (Gain) From Sale of Investments | -500.00K | -505.00K | 2.40M | ||
| Loss (Gain) on Equity Investments | 3.54M | ||||
| Stock-Based Compensation | 26.23M | 16.40M | 9.65M | 8.75M | 6.74M |
| Other Operating Activities | 3.28M | 3.15M | 12.30M | 7.07M | 2.48M |
| Change in Accounts Payable | -1.46M | -27.00K | -204.00K | 399.00K | -3.78M |
| Change in Other Net Operating Assets | -2.91M | -2.25M | -1.32M | -6.71M | 541.00K |
| Operating Cash Flow | -106.54M | -111.94M | 75.95M | -86.83M | -99.20M |
| Capital Expenditures | -302.00K | -794.00K | -1.15M | -441.00K | -1.97M |
| Investment in Securities | -292.20M | -170.17M | -1.20M | ||
| Investing Cash Flow | -292.50M | -170.96M | -1.15M | -441.00K | -3.17M |
| Long-Term Debt Issued | 24.48M | 16.18M | |||
| Net Debt Issued (Repaid) | 39.40M | 24.48M | 16.18M | ||
| Issuance of Common Stock | 297.33M | 275.84M | 733.00K | 209.00K | 154.00K |
| Other Financing Activities | 408.00K | -500.00K | -3.15M | ||
| Financing Cash Flow | 337.14M | 275.34M | 92.85M | 16.39M | 1.73M |
| Net Cash Flow | -61.90M | -7.57M | 167.65M | -70.88M | -100.64M |
| Free Cash Flow | -106.84M | -112.73M | 74.81M | -87.27M | -101.17M |
| Free Cash Flow Margin | -534.20% | 44.66% | |||
| Free Cash Flow Per Share | -2.01 | -2.62 | 27.40 | -38.14 | -50.33 |
| Levered Free Cash Flow | -63.63M | -72.52M | 52.09M | -52.55M | |
| Unlevered Free Cash Flow | -63.00M | -72.52M | 52.09M | -52.55M | |
| Cash Income Tax Paid | 1.23M | ||||
| Change in Working Capital | -4.37M | -2.27M | -1.52M | -6.32M | -3.24M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 1.70B | 1.99B | |||
| Enterprise Value | 1.26B | 1.63B | |||
| Last Close Price | 31.48 | 41.43 | |||
| PB Ratio | 3.86 | 5.62 | |||
| P/TBV Ratio | 3.75 | 5.62 | |||
| Debt / Equity Ratio | 0.13 | 0.07 | 0.14 | 4.94 | 0.32 |
| Debt / EBITDA Ratio | 0.40 | ||||
| Debt / FCF Ratio | 0.36 | ||||
| Net Debt / Equity Ratio | -0.96 | -0.90 | -0.86 | 2.04 | -0.67 |
| Net Debt / EBITDA Ratio | 3.02 | 2.27 | -2.79 | -0.22 | 0.63 |
| Net Debt / FCF Ratio | 4.07 | 2.83 | -2.27 | -0.23 | 0.67 |
| Asset Turnover | 0.05 | 1.07 | |||
| Quick Ratio | 18.03 | 15.22 | 9.52 | 1.79 | 4.81 |
| Current Ratio | 18.31 | 15.50 | 9.76 | 2.09 | 5.11 |
| Return on Equity (ROE) | -37.35% | -47.52% | 50.48% | -180.12% | |
| Return on Assets (ROA) | -21.79% | -28.01% | 23.07% | -55.62% | |
| Return on Invested Capital (ROIC) | -190.34% | -453.11% | 196.80% | -307.50% | -330.64% |
| Return on Capital Employed (ROCE) | -28.60% | -38.20% | 26.20% | -178.60% | -86.00% |
| Earnings Yield | -8.00% | -6.58% | |||
| FCF Yield | -6.29% | -5.66% | |||
| Buyback Yield / Dilution | -174.46% | -1,474.04% | -19.33% | -13.82% |